The potential for selective cyclin-dependent kinase 4/6 inhibition in the therapy for head and neck squamous cell carcinoma
D Adkins, J Ley, J Cohen, P Oppelt - The Cancer Journal, 2022 - journals.lww.com
Preclinical data support investigation of selective CDK4/6 inhibition as a therapeutic strategy
for human papillomavirus (HPV)–unrelated head and neck squamous cell carcinoma …
for human papillomavirus (HPV)–unrelated head and neck squamous cell carcinoma …
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 …
D Adkins, J Ley, P Neupane, F Worden… - The lancet …, 2019 - thelancet.com
Background Most head and neck squamous-cell carcinomas (HNSCCs) are driven by p16
INK4A inactivation and cyclin D1 overexpression that results in hyperactivation of cyclin …
INK4A inactivation and cyclin D1 overexpression that results in hyperactivation of cyclin …
Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized …
D Adkins, JC Lin, AG Sacco, JC Ley, P Oppelt, Q Shen… - 2019 - ascopubs.org
6013 Background: Cetuximab monotherapy results in a median overall survival (OS) of
approximately 6 months (mo) in platinum-resistant recurrent/metastatic head and neck …
approximately 6 months (mo) in platinum-resistant recurrent/metastatic head and neck …
A Phase I Study of the CDK4/6 Inhibitor Palbociclib in Combination with Cetuximab and Radiotherapy for Locally Advanced Head and Neck Squamous Cell …
N Ngamphaiboon, P Pattaranutaporn, S Lukerak… - Clinical Cancer …, 2024 - AACR
Purpose: Palbociclib, a cyclin D kinase 4 (CDK4)/6 inhibitor, has shown radiosensitizing
effects in preclinical studies. There is a strong rationale for adding palbociclib to cetuximab …
effects in preclinical studies. There is a strong rationale for adding palbociclib to cetuximab …
Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4/6 inhibitor, and cetuximab in platinum-resistant HPV unrelated (-) recurrent …
D Adkins, PJ Oppelt, JC Ley, K Trinkaus, PC Neupane… - 2018 - ascopubs.org
6008 Background: In platinum-resistant RM-HNSCC, the efficacy of cetuximab is modest
with a tumor response rate of 13%, median time to progression of 2.3 months and median …
with a tumor response rate of 13%, median time to progression of 2.3 months and median …
A phase I trial of the addition of the CDK 4/6 inhibitor palbociclib to cetuximab in patients with incurable head and neck squamous cell carcinoma (HNSCC).
LS Michel, JC Ley, TM Wildes, K Trinkaus, D Adkins - 2015 - ascopubs.org
6043 Background: Overexpression of cyclin D1 and inactivation of p16 occur in the majority
(> 90%) of HPV-unrelated HNSCC. Resistance to cetuximab and cisplatin, the two most …
(> 90%) of HPV-unrelated HNSCC. Resistance to cetuximab and cisplatin, the two most …
Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma
Z Gu, C Shi, J Li, Y Han, B Sun, W Zhang, J Wu, G Zhou… - BMC medicine, 2022 - Springer
Background Deregulation of cell-cycle pathway is ubiquitously observed in human
papillomavirus negative (HPVneg) head and neck squamous cell carcinoma (HNSCC) …
papillomavirus negative (HPVneg) head and neck squamous cell carcinoma (HNSCC) …
An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 study of palbociclib (an oral CDK4/6 inhibitor) plus cetuximab in …
B Keam, M Tahara, JC Lin, AG Sacco, B Melichar… - 2016 - ascopubs.org
TPS6102 Background: SCCHN is the sixth most common cancer worldwide. Current second-
line treatments for human papillomavirus (HPV)–negative, R/M SCCHN have marginal …
line treatments for human papillomavirus (HPV)–negative, R/M SCCHN have marginal …
Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial
P Oppelt, JC Ley, F Worden, K Palka, R Maggiore, J Liu… - Oral Oncology, 2021 - Elsevier
Objectives We previously reported that palbociclib, a selective CDK4/6 inhibitor, given with
cetuximab, resulted in an objective response rate (ORR) of 19% in cetuximab-resistant …
cetuximab, resulted in an objective response rate (ORR) of 19% in cetuximab-resistant …
Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck …
L Michel, J Ley, TM Wildes, A Schaffer, A Robinson… - Oral oncology, 2016 - Elsevier
Objectives To test the safety of the CDK4/6 inhibitor palbociclib with cetuximab in patients
with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Materials and …
with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Materials and …
相关搜索
- oropharynx squamous cell carcinoma
- therapy for head cell carcinoma
- cetuximab in patients cell carcinoma
- combination with cetuximab cell carcinoma
- incurable head cell carcinoma
- cetuximab and radiotherapy cell carcinoma
- inhibitor palbociclib cell carcinoma
- inhibitor ribociclib head and neck
- cetuximab and radiotherapy palbociclib in combination
- palbociclib in combination cell carcinoma
- inhibitor ribociclib cell carcinoma
- incurable head inhibitor palbociclib